Daunorubicin

Biliary Tract Cancer

RenJi HospitalPhase 2Active

CCC

51/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 73/ 100

Competitive context

64 Active assets in the Biliary Tract Cancer cohort.

Asset / Sponsor	Phase	Rating
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC	Phase 3	BB
Epirubicin Merck Sharp & Dohme LLC	Phase 3	BB
Cyclophosphamide Zhejiang University	Phase 3	BB
Pembrolizumab Merck Sharp & Dohme LLC	Phase 3	BB
Calcium folinate pentahydrate Shenzhen Xinhe Biomedical	Phase 2	BB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant

BBB

Indicative ·

78 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

77 / 100

acute monocytic leukemiaDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.